RT Journal Article SR Electronic T1 Where are we with RSV prophylaxis? JF Archives of disease in childhood - Education & practice edition JO Arch Dis Child Educ Pract Ed FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health SP 38 OP 42 DO 10.1136/archdischild-2015-308780 VO 101 IS 1 A1 Neil A Caldwell A1 Ceri Townsend YR 2016 UL http://ep.bmj.com/content/101/1/38.abstract AB Respiratory syncytial virus (RSV) is a predictable, seasonal disease with significant morbidity and mortality in children below 24 months. Prophylaxis, which decreases hospitalisation in those most vulnerable to the disease, has been available since 1998. Pharmacological prophylaxis is however, expensive and requires good infrastructure to deliver. It is out of reach for many patients in low-income and middle-income countries where mortality is highest. This article looks at the pathophysiology and risk factors for RSV. It also outlines what agents are currently available for prophylaxis and prevention.